Thomas Pietschmann

List of Publications by Year in Descending Order

142 papers	10,338 citations	46 h-index	100 g-index
161 ext. papers	11,472 ext. citations	8.8 avg, IF	5.75 L-index

#	Paper	IF	Citations
142	Intra-host analysis of hepaciviral glycoprotein evolution reveals signatures associated with viral persistence and clearance.. *Virus Evolution*, **2022**, 8, veac007	3.7	1
141	Differential interferon-subtype induced immune signatures are associated with suppression of SARS-CoV-2 infection.. *Proceedings of the National Academy of Sciences of the United States of America*, **2022**, 119,	11.5	1
140	Sandacrabins - Structurally Unique Antiviral RNA Polymerase Inhibitors from a Rare Myxobacterium.. *Chemistry - A European Journal*, **2022**, e202104484	4.8	0
139	The Human Liver-Expressed Lectin CD302 Restricts Hepatitis C Virus Infection.. *Journal of Virology*, **2022**, e0199521	6.6	0
138	IRIS: Infection with RespIratory Syncytial Virus in infants-a prospective observational cohort study.. *BMC Pulmonary Medicine*, **2022**, 22, 88	3.5	0
137	Analysis of antibodies from HCV elite neutralizers identifies genetic determinants of broad neutralization.. *Immunity*, **2021**,	32.3	1
136	Hepatitis C reference viruses highlight potent antibody responses and diverse viral functional interactions with neutralising antibodies. *Gut*, **2021**, 70, 1734-1745	19.2	5
135	Initial HCV infection of adult hepatocytes triggers a temporally structured transcriptional program containing diverse pro- and anti-viral elements. *Journal of Virology*, **2021**,	6.6	3
134	A condensate-hardening drug blocks RSV replication in vivo. *Nature*, **2021**, 595, 596-599	50.4	25
133	Magnesium Complexes of Ladanein: A Beneficial Strategy for Stabilizing Polyphenolic Antivirals. *European Journal of Inorganic Chemistry*, **2021**, 2021, 2764-2772	2.3	1
132	Liver-expressed and limit hepatitis C virus cross-species transmission to mice. *Science Advances*, **2020**, 6,	14.3	9
131	Filovirus Antiviral Activity of Cationic Amphiphilic Drugs Is Associated with Lipophilicity and Ability To Induce Phospholipidosis. *Antimicrobial Agents and Chemotherapy*, **2020**, 64,	5.9	8
130	The ATGL lipase cooperates with ABHD5 to mobilize lipids for hepatitis C virus assembly. *PLoS Pathogens*, **2020**, 16, e1008554	7.6	10
129	Controlled Functional Zonation of Hepatocytes by Engineering of Wnt Signaling. *ACS Synthetic Biology*, **2020**, 9, 1638-1649	5.7	4
128	Efficient acute and chronic infection of stem cell-derived hepatocytes by hepatitis C virus. *Gut*, **2020**, 69, 1659-1666	19.2	5
127	Labyrinthopeptins as virolytic inhibitors of respiratory syncytial virus cell entry. *Antiviral Research*, **2020**, 177, 104774	10.8	19
126	Protecting-Group-Mediated Diastereoselective Synthesis of C4RMethylated Uridine Analogs and Their Activity against the Human Respiratory Syncytial Virus. *Journal of Organic Chemistry*, **2020**, 85, 4267-4278	4.3	3

125	Single-nucleotide variants in human CD81 influence hepatitis C virus infection of hepatoma cells. *Medical Microbiology and Immunology*, **2020**, 209, 499-514	4	3
124	Labyrinthopeptins Exert Broad-Spectrum Antiviral Activity through Lipid-Binding-Mediated Virolysis. *Journal of Virology*, **2020**, 94,	6.6	18
123	OCIAD1 is a host mitochondrial substrate of the hepatitis C virus NS3-4A protease. *PLoS ONE*, **2020**, 15, e0236447	3.7	3
122	Hepatitis C Virus Entry: Protein Interactions and Fusion Determinants Governing Productive Hepatocyte Invasion. *Cold Spring Harbor Perspectives in Medicine*, **2020**, 10,	5.4	23
121	C19orf66 is an interferon-induced inhibitor of HCV replication that restricts formation of the viral replication organelle. *Journal of Hepatology*, **2020**, 73, 549-558	13.4	10
120	Tracking Hepatitis C Virus Interactions with the Hepatic Lipid Metabolism **2020**, 889-905		1
119	Synthesis of 4′,5′-Spirocyclopropanated Uridine and d-Xylouridine Derivatives and Their Activity against the Human Respiratory Syncytial Virus. *Organic Letters*, **2019**, 21, 6966-6971	6.2	10
118	Hepatitis C Virus. *Trends in Microbiology*, **2019**, 27, 379-380	12.4	21
117	Identification of Keratin 23 as a Hepatitis C Virus-Induced Host Factor in the Human Liver. *Cells*, **2019**, 8,	7.9	2
116	HCV Pit Stop at the Lipid Droplet: Refuel Lipids and Put on a Lipoprotein Coat before Exit. *Cells*, **2019**, 8,	7.9	26
115	Characterization of the Filovirus-Resistant Cell Line SH-SY5Y Reveals Redundant Role of Cell Surface Entry Factors. *Viruses*, **2019**, 11,	6.2	6
114	Physicochemical Properties Govern the Activity of Potent Antiviral Flavones. *ACS Omega*, **2019**, 4, 4871-4887	3.9	5
113	Cohort Profile: The LoewenKIDS Study - life-course perspective on infections, the microbiome and the development of the immune system in early childhood. *International Journal of Epidemiology*, **2019**, 48, 1042-1043h	7.8	2
112	A central hydrophobic E1 region controls the pH range of hepatitis C virus membrane fusion and susceptibility to fusion inhibitors. *Journal of Hepatology*, **2019**, 70, 1082-1092	13.4	12
111	Functional and immunogenic characterization of diverse HCV glycoprotein E2 variants. *Journal of Hepatology*, **2019**, 70, 593-602	13.4	11
110	Hepatitis E virus replication and interferon responses in human placental cells. *Hepatology Communications*, **2018**, 2, 173-187	6	26
109	Critical challenges and emerging opportunities in hepatitis C virus research in an era of potent antiviral therapy: Considerations for scientists and funding agencies. *Virus Research*, **2018**, 248, 53-62	6.4	95
108	CD81 Receptor Regions outside the Large Extracellular Loop Determine Hepatitis C Virus Entry into Hepatoma Cells. *Viruses*, **2018**, 10,	6.2	9

107	Hepatitis C virus enters liver cells using the CD81 receptor complex proteins calpain-5 and CBLB. *PLoS Pathogens*, **2018**, 14, e1007111	7.6	29
106	Molecular characteristics and successful management of a respiratory syncytial virus outbreak among pediatric patients with hemato-oncological disease. *Antimicrobial Resistance and Infection Control*, **2018**, 7, 21	6.2	1
105	The Small-Compound Inhibitor K22 Displays Broad Antiviral Activity against Different Members of the Family Flaviviridae and Offers Potential as a Panviral Inhibitor. *Antimicrobial Agents and Chemotherapy*, **2018**, 62,	5.9	8
104	Tracking HCV protease population diversity during transmission and susceptibility of founder populations to antiviral therapy. *Antiviral Research*, **2017**, 139, 129-137	10.8	4
103	Protein Interactions during the Flavivirus and Hepacivirus Life Cycle. *Molecular and Cellular Proteomics*, **2017**, 16, S75-S91	7.6	40
102	Immune protection against reinfection with nonprimate hepacivirus. *Proceedings of the National Academy of Sciences of the United States of America*, **2017**, 114, E2430-E2439	11.5	36
101	Maturation of secreted HCV particles by incorporation of secreted ApoE protects from antibodies by enhancing infectivity. *Journal of Hepatology*, **2017**, 67, 480-489	13.4	38
100	Conformational Flexibility in the Immunoglobulin-Like Domain of the Hepatitis C Virus Glycoprotein E2. *MBio*, **2017**, 8,	7.8	23
99	Virucidal Activity of World Health Organization-Recommended Formulations Against Enveloped Viruses, Including Zika, Ebola, and Emerging Coronaviruses. *Journal of Infectious Diseases*, **2017**, 215, 902-906	7	110
98	Pentagalloylglucose, a highly bioavailable polyphenolic compound present in Cortex moutan, efficiently blocks hepatitis C virus entry. *Antiviral Research*, **2017**, 147, 19-28	10.8	18
97	Hepatitis C Virus Strain-Dependent Usage of Apolipoprotein E Modulates Assembly Efficiency and Specific Infectivity of Secreted Virions. *Journal of Virology*, **2017**, 91,	6.6	15
96	Synthetic Polymer with a Structure-Driven Hepatic Deposition and Curative Pharmacological Activity in Hepatic Cells. *ACS Macro Letters*, **2017**, 6, 935-940	6.6	4
95	Clinically Approved Ion Channel Inhibitors Close Gates for Hepatitis C Virus and Open Doors for Drug Repurposing in Infectious Viral Diseases. *Journal of Virology*, **2017**, 91,	6.6	14
94	Decoding protein networks during virus entry by quantitative proteomics. *Virus Research*, **2016**, 218, 25-39	6.4	18
93	Targeting a host-cell entry factor barricades antiviral-resistant HCV variants from on-therapy breakthrough in human-liver mice. *Gut*, **2016**, 65, 2029-2034	19.2	16
92	Apolipoprotein E polymorphisms and their protective effect on hepatitis E virus replication. *Hepatology*, **2016**, 64, 2274-2276	11.2	4
91	Expanding the Host Range of Hepatitis C Virus through Viral Adaptation. *MBio*, **2016**, 7,	7.8	8
90	Antiviral Activities of Different Interferon Types and Subtypes against Hepatitis E Virus Replication. *Antimicrobial Agents and Chemotherapy*, **2016**, 60, 2132-9	5.9	58

89	Ion Channel Function and Cross-Species Determinants in Viral Assembly of Nonprimate Hepacivirus p7. *Journal of Virology*, **2016**, 90, 5075-5089	6.6	4
88	Distinct Escape Pathway by Hepatitis C Virus Genotype 1a from a Dominant CD8+ T Cell Response by Selection of Altered Epitope Processing. *Journal of Virology*, **2016**, 90, 33-42	6.6	11
87	ABHD5/CGI-58, the Chanarin-Dorfman Syndrome Protein, Mobilises Lipid Stores for Hepatitis C Virus Production. *PLoS Pathogens*, **2016**, 12, e1005568	7.6	20
86	Hepatitis C Virus Stimulates Murine CD8Like Dendritic Cells to Produce Type I Interferon in a TRIF-Dependent Manner. *PLoS Pathogens*, **2016**, 12, e1005736	7.6	4
85	Flunarizine prevents hepatitis C virus membrane fusion in a genotype-dependent manner by targeting the potential fusion peptide within E1. *Hepatology*, **2016**, 63, 49-62	11.2	53
84	cGAS-Mediated Innate Immunity Spreads Intercellularly through HIV-1 Env-Induced Membrane Fusion Sites. *Cell Host and Microbe*, **2016**, 20, 443-457	23.4	33
83	Hepacivirus NS3/4A Proteases Interfere with MAVS Signaling in both Their Cognate Animal Hosts and Humans: Implications for Zoonotic Transmission. *Journal of Virology*, **2016**, 90, 10670-10681	6.6	17
82	Soraphen A: A broad-spectrum antiviral natural product with potent anti-hepatitis C virus activity. *Journal of Hepatology*, **2015**, 63, 813-21	13.4	26
81	Identification of a Human Respiratory Syncytial Virus Cell Entry Inhibitor by Using a Novel Lentiviral Pseudotype System. *Journal of Virology*, **2015**, 90, 3065-73	6.6	15
80	Cell culture-derived HCV cannot infect synovial fibroblasts. *Scientific Reports*, **2015**, 5, 18043	4.9	1
79	Interferon-inducible cholesterol-25-hydroxylase restricts hepatitis C virus replication through blockage of membranous web formation. *Hepatology*, **2015**, 62, 702-14	11.2	56
78	Genetic Diversity Underlying the Envelope Glycoproteins of Hepatitis C Virus: Structural and Functional Consequences and the Implications for Vaccine Design. *Viruses*, **2015**, 7, 3995-4046	6.2	38
77	Efficient virus assembly, but not infectivity, determines the magnitude of hepatitis C virus-induced interferon alpha responses of plasmacytoid dendritic cells. *Journal of Virology*, **2015**, 89, 3200-8	6.6	9
76	Quantitative Proteomics Identifies Serum Response Factor Binding Protein 1 as a Host Factor for Hepatitis C Virus Entry. *Cell Reports*, **2015**, 12, 864-78	10.6	40
75	Clinical course of infection and viral tissue tropism of hepatitis C virus-like nonprimate hepaciviruses in horses. *Hepatology*, **2015**, 61, 447-59	11.2	99
74	Control of hepatitis C virus replication in mouse liver-derived cells by MAVS-dependent production of type I and type III interferons. *Journal of Virology*, **2015**, 89, 3833-45	6.6	16
73	Mechanisms of methods for hepatitis C virus inactivation. *Applied and Environmental Microbiology*, **2015**, 81, 1616-21	4.8	30
72	Several Human Liver Cell Expressed Apolipoproteins Complement HCV Virus Production with Varying Efficacy Conferring Differential Specific Infectivity to Released Viruses. *PLoS ONE*, **2015**, 10, e0134529	3.7	22

71	A molecular tweezer antagonizes seminal amyloids and HIV infection. *ELife*, **2015**, 4,	8.9	55
70	Assessment of cross-species transmission of hepatitis C virus-related non-primate hepacivirus in a population of humans at high risk of exposure. *Journal of General Virology*, **2015**, 96, 2636-2642	4.9	16
69	Turmeric curcumin inhibits entry of all hepatitis C virus genotypes into human liver cells. *Gut*, **2014**, 63, 1137-49	19.2	119
68	Successful anti-scavenger receptor class B type I (SR-BI) monoclonal antibody therapy in humanized mice after challenge with HCV variants with in vitro resistance to SR-BI-targeting agents. *Hepatology*, **2014**, 60, 1508-18	11.2	43
67	Role of hypervariable region 1 for the interplay of hepatitis C virus with entry factors and lipoproteins. *Journal of Virology*, **2014**, 88, 12644-55	6.6	35
66	Development of a high-throughput pyrosequencing assay for monitoring temporal evolution and resistance associated variant emergence in the Hepatitis C virus protease coding-region. *Antiviral Research*, **2014**, 110, 52-9	10.8	10
65	Incorporation of primary patient-derived glycoproteins into authentic infectious hepatitis C virus particles. *Hepatology*, **2014**, 60, 508-20	11.2	7
64	Isolate-dependent use of claudins for cell entry by hepatitis C virus. *Hepatology*, **2014**, 59, 24-34	11.2	44
63	In sero veritas: what serum markers teach us about HCV infection of primary human hepatocytes. *Gut*, **2014**, 63, 1375-7	19.2	2
62	Natural reservoirs for homologs of hepatitis C virus. *Emerging Microbes and Infections*, **2014**, 3, e21	18.9	65
61	Incorporation of hepatitis C virus E1 and E2 glycoproteins: the keystones on a peculiar virion. *Viruses*, **2014**, 6, 1149-87	6.2	45
60	Analysis of serine codon conservation reveals diverse phenotypic constraints on hepatitis C virus glycoprotein evolution. *Journal of Virology*, **2014**, 88, 667-78	6.6	2
59	The HCV life cycle: in vitro tissue culture systems and therapeutic targets. *Digestive Diseases*, **2014**, 32, 525-37	3.2	22
58	Hepatitis C virus hypervariable region 1 variants presented on hepatitis B virus capsid-like particles induce cross-neutralizing antibodies. *PLoS ONE*, **2014**, 9, e102235	3.7	5
57	Apolipoprotein E codetermines tissue tropism of hepatitis C virus and is crucial for viral cell-to-cell transmission by contributing to a postenvelopment step of assembly. *Journal of Virology*, **2014**, 88, 1433-46	6.6	78
56	Cell entry, efficient RNA replication, and production of infectious hepatitis C virus progeny in mouse liver-derived cells. *Hepatology*, **2014**, 59, 78-88	11.2	34
55	Entry and replication of recombinant hepatitis C viruses in cell culture. *Methods*, **2013**, 59, 233-48	4.6	39
54	Hepatitis C virus replication in mouse cells is restricted by IFN-dependent and -independent mechanisms. *Gastroenterology*, **2013**, 145, 1414-23.e1	13.3	27

53	Interferon lambda 4 signals via the IFNλ receptor to regulate antiviral activity against HCV and coronaviruses. *EMBO Journal*, **2013**, 32, 3055-65	13	148
52	Opportunities and Risks of Host-targeting Antiviral Strategies for Hepatitis C. *Current Hepatitis Reports*, **2013**, 12, 200-213		4
51	Two pathogen reduction technologies--methylene blue plus light and shortwave ultraviolet light--effectively inactivate hepatitis C virus in blood products. *Transfusion*, **2013**, 53, 1010-8	2.9	42
50	Cell culture systems for hepatitis C virus. *Current Topics in Microbiology and Immunology*, **2013**, 369, 17-48	3.3	65
49	Characterization of the inhibition of hepatitis C virus entry by in vitro-generated and patient-derived oxidized low-density lipoprotein. *Hepatology*, **2013**, 57, 1716-24	11.2	12
48	Hepatitis C virus NS5B polymerase primes innate immune signaling. *Hepatology*, **2013**, 57, 1275-7	11.2	0
47	hepatitis c Virus p7 is critical for capsid assembly and envelopment. *PLoS Pathogens*, **2013**, 9, e1003355	7.6	92
46	Inactivation of hepatitis C virus infectivity by human breast milk. *Journal of Infectious Diseases*, **2013**, 208, 1943-52	7	37
45	Transmission of hepatitis C virus among people who inject drugs: viral stability and association with drug preparation equipment. *Journal of Infectious Diseases*, **2013**, 207, 281-7	7	50
44	Characterization of hepatitis C virus intra- and intergenotypic chimeras reveals a role of the glycoproteins in virus envelopment. *Journal of Virology*, **2013**, 87, 13297-306	6.6	18
43	Subcellular localization and function of an epitope-tagged p7 viroporin in hepatitis C virus-producing cells. *Journal of Virology*, **2013**, 87, 1664-78	6.6	38
42	The postbinding activity of scavenger receptor class B type I mediates initiation of hepatitis C virus infection and viral dissemination. *Hepatology*, **2013**, 57, 492-504	11.2	60
41	A plant-derived flavonoid inhibits entry of all HCV genotypes into human hepatocytes. *Gastroenterology*, **2012**, 143, 213-22.e5	13.3	84
40	Mutations that alter use of hepatitis C virus cell entry factors mediate escape from neutralizing antibodies. *Gastroenterology*, **2012**, 143, 223-233.e9	13.3	60
39	Total synthesis of a noricumazole A library and evaluation of HCV inhibition. *Chemistry - A European Journal*, **2012**, 18, 9083-90	4.8	15
38	MAP-kinase regulated cytosolic phospholipase A2 activity is essential for production of infectious hepatitis C virus particles. *PLoS Pathogens*, **2012**, 8, e1002829	7.6	94
37	Escape from a dominant HLA-B*15-restricted CD8+ T cell response against hepatitis C virus requires compensatory mutations outside the epitope. *Journal of Virology*, **2012**, 86, 991-1000	6.6	17
36	Bile acids specifically increase hepatitis C virus RNA-replication. *PLoS ONE*, **2012**, 7, e36029	3.7	20

35	EGFR and EphA2 are host factors for hepatitis C virus entry and possible targets for antiviral therapy. *Nature Medicine*, **2011**, 17, 589-95	50.5	511
34	Hepatitis C virus complete life cycle screen for identification of small molecules with pro- or antiviral activity. *Antiviral Research*, **2011**, 89, 136-48	10.8	39
33	The green tea polyphenol, epigallocatechin-3-gallate, inhibits hepatitis C virus entry. *Hepatology*, **2011**, 54, 1947-55	11.2	207
32	Impact of intra- and interspecies variation of occludin on its function as coreceptor for authentic hepatitis C virus particles. *Journal of Virology*, **2011**, 85, 7613-21	6.6	39
31	Completion of hepatitis C virus replication cycle in heterokaryons excludes dominant restrictions in human non-liver and mouse liver cell lines. *PLoS Pathogens*, **2011**, 7, e1002029	7.6	22
30	Inactivation and survival of hepatitis C virus on inanimate surfaces. *Journal of Infectious Diseases*, **2011**, 204, 1830-8	7	80
29	NMR structure and ion channel activity of the p7 protein from hepatitis C virus. *Journal of Biological Chemistry*, **2010**, 285, 31446-61	5.4	113
28	Hepatitis C virus hypervariable region 1 modulates receptor interactions, conceals the CD81 binding site, and protects conserved neutralizing epitopes. *Journal of Virology*, **2010**, 84, 5751-63	6.6	174
27	Mouse-specific residues of claudin-1 limit hepatitis C virus genotype 2a infection in a human hepatocyte cell line. *Journal of Virology*, **2010**, 84, 964-75	6.6	46
26	How stable is the hepatitis C virus (HCV)? Environmental stability of HCV and its susceptibility to chemical biocides. *Journal of Infectious Diseases*, **2010**, 201, 1859-66	7	63
25	Adaptation of hepatitis C virus to mouse CD81 permits infection of mouse cells in the absence of human entry factors. *PLoS Pathogens*, **2010**, 6, e1000978	7.6	86
24	Hepatitis C virus p7-a viroporin crucial for virus assembly and an emerging target for antiviral therapy. *Viruses*, **2010**, 2, 2078-95	6.2	37
23	Glucocorticosteroids increase cell entry by hepatitis C virus. *Gastroenterology*, **2010**, 138, 1875-84	13.3	63
22	Virucidal activity of 2 alcohol-based formulations proposed as hand rubs by the World Health Organization. *American Journal of Infection Control*, **2010**, 38, 66-8	3.8	29
21	Production of infectious genotype 1b virus particles in cell culture and impairment by replication enhancing mutations. *PLoS Pathogens*, **2009**, 5, e1000475	7.6	105
20	Low pH-dependent hepatitis C virus membrane fusion depends on E2 integrity, target lipid composition, and density of virus particles. *Journal of Biological Chemistry*, **2009**, 284, 17657-67	5.4	74
19	Characterization of determinants important for hepatitis C virus p7 function in morphogenesis by using trans-complementation. *Journal of Virology*, **2009**, 83, 11682-93	6.6	63
18	A lymphotoxin-driven pathway to hepatocellular carcinoma. *Cancer Cell*, **2009**, 16, 295-308	24.3	306

17	Full-length infectious HCV chimeras. *Methods in Molecular Biology*, **2009**, 510, 347-59	1.4	7
16	CD81 is dispensable for hepatitis C virus cell-to-cell transmission in hepatoma cells. *Journal of General Virology*, **2009**, 90, 48-58	4.9	147
15	Efficient trans-encapsidation of hepatitis C virus RNAs into infectious virus-like particles. *Journal of Virology*, **2008**, 82, 7034-46	6.6	120
14	Structural and functional characterization of nonstructural protein 2 for its role in hepatitis C virus assembly. *Journal of Biological Chemistry*, **2008**, 283, 28546-62	5.4	124
13	Antiviral effects of amantadine and iminosugar derivatives against hepatitis C virus. *Hepatology*, **2007**, 46, 330-8	11.2	117
12	Scavenger receptor class B type I is a key host factor for hepatitis C virus infection required for an entry step closely linked to CD81. *Hepatology*, **2007**, 46, 1722-31	11.2	209
11	Hepatitis C virus p7 protein is crucial for assembly and release of infectious virions. *PLoS Pathogens*, **2007**, 3, e103	7.6	266
10	Analysis of hepatitis C virus superinfection exclusion by using novel fluorochrome gene-tagged viral genomes. *Journal of Virology*, **2007**, 81, 4591-603	6.6	174
9	The level of CD81 cell surface expression is a key determinant for productive entry of hepatitis C virus into host cells. *Journal of Virology*, **2007**, 81, 588-98	6.6	185
8	Characterization of the hepatitis C virus E2 epitope defined by the broadly neutralizing monoclonal antibody AP33. *Hepatology*, **2006**, 43, 592-601	11.2	132
7	Characterization of the early steps of hepatitis C virus infection by using luciferase reporter viruses. *Journal of Virology*, **2006**, 80, 5308-20	6.6	343
6	Construction and characterization of infectious intragenotypic and intergenotypic hepatitis C virus chimeras. *Proceedings of the National Academy of Sciences of the United States of America*, **2006**, 103, 7408-13	11.5	600
5	High density lipoprotein inhibits hepatitis C virus-neutralizing antibodies by stimulating cell entry via activation of the scavenger receptor BI. *Journal of Biological Chemistry*, **2006**, 281, 18285-95	5.4	169
4	Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. *Nature Medicine*, **2005**, 11, 791-6	50.5	2303
3	Novel insights into hepatitis C virus replication and persistence. *Advances in Virus Research*, **2004**, 63, 71-180	10.7	218
2	Mutations that permit efficient replication of hepatitis C virus RNA in Huh-7 cells prevent productive replication in chimpanzees. *Proceedings of the National Academy of Sciences of the United States of America*, **2002**, 99, 14416-21	11.5	214
1	Foamy virus capsids require the cognate envelope protein for particle export. *Journal of Virology*, **1999**, 73, 2613-21	6.6	126